KAER specializes in new inhalation therapies that are made possible by KAER’s worldwide patent protected, game-changing aerosol delivery system, SUPRAER. SUPRAER aerosol generation and processing technology enables rapid delivery to the lungs of high doses of respirable aerosols of biotherapeutics including, surfactant, proteins, antibodies, antibiotics, and of course, small molecules. While KAER licenses the aerosol delivery technology to its strategic partners to deliver their agents, its internal focus is on aerosol surfactant replacement therapy for acute lung injury, acute respiratory distress syndrome (ARDS) and neonatal RDS. ARDS afflicts 200,000 Americans each year. Present standard care is limited to life support. KAER plans to markedly reduce the present 40% mortality rate in mild early-stage patients. KAER provides services and devices for the generation and delivery of respirable aerosols. KAER’s primary competitive advantage is in the generation and delivery of high concentrations of aerosols of large labile molecules. KAER addresses the needs of the pharmaceutical, biotechnological and toxicological industries. SUPRAER-CA Model 3 has the CE mark and the Nemko safety mark for the USA and Canada. Each unit has a unique identification number and labelled according to Mil-SPC-130. ➢ The development of these technologies was funded by $2M in NIH SBIR grants. Dr Yeates was the primary inventor of these technologies. ➢ The high dose rate aerosol delivery system is a new class of aerosol delivery system providing Pharma with a new platform to deliver their biotherapeutic or large labile molecule to the lungs.KAER BioTherapeutics received the Frost and Sullivan 2012 North American Technology Innovation Award for Aerosol Drug Delivery.http://www.kaerbio.com Frost and Sullivan sent out a news of this award on PR NewsWire on Feb 26th,

• Cofounded BioTechPlex to develop new biomedical technologies using SBIR funding. • Developed a large range of technologies were develop with 11 phase I grants and 9 phase II grants totaling $12M. • 3 additional companies were incorporated to commercialize the technologies; KAER Biotherapeutics being the one headed by Dr. Yeates. . • KAER Biotherapeutics is the surviving company for the commercialization of the intellectual property related to aerosol generation and delivery developed within BioTechPlex.

➢ Promoted to Professor in Departments of Medicine (with tenure) and Bioengineering, University of Illinois at Chicago, Illinois. ➢ Chief, Section of Environmental and Occupational Medicine, 1989-1996➢ Created a section of Environmental and occupational Medicine within the Department of Medicine with both clinical and research programs.➢ Director Occupational Health and Safety Center. 1998-1990➢ Successfully turned around the scientifically disapproved the Great Lakes Occupation Health and Safety center with programs in Occupational Medicine, Industrial Hygiene, Occupation Nursing, Safely Engineering, and Continuing education. ➢ Directed an NIH funded research program in aerosol deposition and clearance involving humans, dogs, baboons and rats.

➢ Promoted to Senior Research Career Scientist➢ Dr. Yeates directed a VA funded research program in lung physiology